| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
tert-Butyl 3-oxoazetidine-1-carboxylate does not have a defined biological target as it is a synthetic intermediate rather than a pharmacologically active compound. Its function is chemical—it serves as a building block for the synthesis of more complex molecules. The azetidinone ring is a strained four-membered cyclic ketone that can undergo ring-opening reactions. The Boc group protects the nitrogen during synthesis and can be removed under acidic conditions. When incorporated into pharmaceutical compounds, the azetidine scaffold can interact with biological targets through hydrogen bonding and hydrophobic interactions. The compound itself is not evaluated for biological activity against specific targets.
|
|---|---|
| ln Vitro |
As a chemical intermediate, tert-butyl 3-oxoazetidine-1-carboxylate exhibits no intrinsic pharmacological activity in vitro. Its utility is demonstrated in organic synthesis as a building block for the preparation of pharmaceuticals and other bioactive compounds. The azetidinone ring can be reduced to the corresponding alcohol, subjected to nucleophilic addition at the ketone, or ring-opened to provide functionalized amine derivatives. In cell-based assays, the compound itself is not tested for biological activity. Instead, the products synthesized from this reagent are evaluated for their pharmacological properties. The compound is used exclusively as a chemical intermediate in organic synthesis and medicinal chemistry research.
|
| ln Vivo |
tert-Butyl 3-oxoazetidine-1-carboxylate does not exhibit in vivo biological activity as it is not a therapeutic agent. The compound is used as a research reagent for organic synthesis. Any in vivo effects would be associated with the final products synthesized from this intermediate, not with the intermediate itself. The compound is not administered to animals in pharmacological studies and has no known physiological effects. Its role is strictly chemical—providing a versatile Boc-protected azetidinone scaffold for constructing complex molecules.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to tert-butyl 3-oxoazetidine-1-carboxylate as it is not a biologically active compound. Standard characterization protocols for this reagent include nuclear magnetic resonance (¹H NMR, ¹³C NMR) and mass spectrometry to confirm structure and purity. Melting point determination and HPLC analysis are used for quality control. For synthetic applications, typical reactions include reduction of the ketone to the alcohol, nucleophilic addition to the ketone, deprotection of the Boc group to reveal the free azetidine, and ring-opening reactions. The resulting products are then evaluated for biological activity.
|
| Cell Assay |
Cell-based experiments are not performed with tert-butyl 3-oxoazetidine-1-carboxylate itself, as it is a chemical reagent rather than a test compound for biological activity. When the compound is used to synthesize drug candidates, those products may be tested in cell culture using standard protocols. Typically, final compounds are dissolved in DMSO and diluted in culture medium to achieve desired concentrations (typically 0.1-100 µM). Cells are incubated for 24-72 hours, and effects on cell viability, proliferation, or specific signaling pathways are measured using appropriate assays. The intermediate itself is not evaluated in cellular systems.
|
| Animal Protocol |
In vivo animal studies are not conducted with tert-butyl 3-oxoazetidine-1-carboxylate, as it is a research reagent for chemical synthesis. When the compound is used to synthesize drug candidates, those final products undergo standard preclinical evaluation. Typical protocols for drug candidates include pharmacokinetic studies in rodents (oral or intravenous administration, blood sampling for LC-MS/MS analysis), efficacy studies in disease models, and toxicology studies (acute and repeated-dose toxicity, histopathology). These studies evaluate the safety and efficacy of the final drug molecules, not the synthetic intermediate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of tert-butyl 3-oxoazetidine-1-carboxylate are not characterized as it is not a drug substance. Based on its physicochemical properties (molecular weight 171.19, logP approximately 0.5-1.0), the compound would be expected to have moderate oral bioavailability if administered. The Boc group would likely be cleaved in vivo to release the free azetidinone, which could undergo further metabolism. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies. For drug candidates synthesized from this intermediate, pharmacokinetic properties are determined as part of drug development.
|
| Toxicity/Toxicokinetics |
tert-Butyl 3-oxoazetidine-1-carboxylate may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored in a cool, dry place away from moisture and strong oxidizing agents. No acute toxicity data are available. The compound is not intended for drug, household, or other uses.
|
| References |
|
| Additional Infomation |
tert-Butyl 3-oxoazetidine-1-carboxylate is a versatile building block in organic synthesis for the preparation of pharmaceuticals and other bioactive compounds. It is also known as N-Boc-3-azetidinone. The azetidine scaffold is a privileged structure in medicinal chemistry. The compound has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is chemical—serving as a precursor for the synthesis of biologically active azetidine derivatives.
|
| Molecular Formula |
C8H13NO3
|
|---|---|
| Molecular Weight |
171.19
|
| Exact Mass |
171.089
|
| CAS # |
398489-26-4
|
| PubChem CID |
1519404
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
251.3±33.0 °C at 760 mmHg
|
| Melting Point |
49-52ºC
|
| Flash Point |
105.8±25.4 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.493
|
| LogP |
-0.34
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
209
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(N1C([H])([H])C(C1([H])[H])=O)=O)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
VMKIXWAFFVLJCK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H13NO3/c1-8(2,3)12-7(11)9-4-6(10)5-9/h4-5H2,1-3H3
|
| Chemical Name |
tert-butyl 3-oxoazetidine-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~584.2 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (14.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8415 mL | 29.2073 mL | 58.4146 mL | |
| 5 mM | 1.1683 mL | 5.8415 mL | 11.6829 mL | |
| 10 mM | 0.5841 mL | 2.9207 mL | 5.8415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
